XBiotech Inc. (XBIT) Financial Ratios
13 years of historical data (2012–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: 5.07
30Y Low5.1·High5.1
P/B Ratio
↓
0.42
↓-51% vs avg
5yr avg: 0.86
30Y Low0.4·High5.6
ROE
↓
-19.2%
↑-90% vs avg
5yr avg: -10.1%
30Y Low-206%·High168%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
XBIT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
XBiotech Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $76M | $120M | $122M | $107M | $334M | $482M | $865M | $182M | $137M | $328M | $335M |
| Enterprise Value | $-86207673 | $-42106129 | $-78269164 | $-50464145 | $97M | $245M | $150M | $166M | $106M | $294M | $244M |
| P/E Ratio → | -1.98 | — | — | — | — | — | 1.29 | — | — | — | — |
| P/S Ratio | — | — | — | 26.64 | 18.18 | 10.96 | — | — | — | — | — |
| P/B Ratio | 0.42 | 0.66 | 0.56 | 0.44 | 1.24 | 1.38 | 1.14 | 4.39 | 2.28 | 5.55 | 3.25 |
| P/FCF | — | — | — | — | 5.07 | — | — | — | — | — | — |
| P/OCF | — | — | — | — | 4.82 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
XBIT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | -12.58 | 5.30 | 5.57 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | 0.21 | — | — | — | — |
| EV / FCF | — | — | — | — | 1.48 | — | — | — | — | — | — |
XBIT Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -19.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 83.8% | 68.4% | 21.5% | — | — | — | — | — |
| Operating Margin | — | — | — | -860.1% | -136.4% | -41.5% | — | — | — | — | — |
| Net Profit Margin | — | — | — | -820.4% | -94.7% | -25.5% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -19.2% | -19.2% | -10.7% | -12.9% | -5.6% | -2.0% | 167.8% | -41.6% | -55.6% | -65.1% | -46.3% |
| ROA | -18.1% | -18.1% | -10.4% | -12.6% | -5.5% | -1.9% | 155.3% | -39.4% | -51.0% | -59.8% | -43.7% |
| ROIC | -164.8% | -164.8% | -55.2% | -44.8% | -26.2% | -18.0% | -70.3% | -58.4% | -96.2% | -215.4% | -410.7% |
| ROCE | -21.0% | -21.0% | -16.2% | -13.4% | -8.1% | -3.3% | -7.8% | -41.3% | -57.1% | -65.1% | -46.3% |
XBIT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $173M exceeds total debt of $10M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | — | — | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.89 | -0.91 | -0.65 | -0.88 | -0.68 | -0.95 | -0.38 | -0.53 | -0.58 | -0.88 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | -3.60 | — | — | — | — | — | — |
| Interest Coverage | -52.63 | -52.63 | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($173M) exceeds total debt ($10M)
XBIT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
XBiotech Inc.'s current ratio of 11.56x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 54.07x to 11.56x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.56 | 11.56 | 33.07 | 54.07 | 71.49 | 81.80 | 11.90 | 5.78 | 11.94 | 4.64 | 14.79 |
| Quick Ratio | 11.56 | 11.56 | 33.07 | 54.07 | 71.49 | 81.80 | 11.90 | 5.78 | 11.94 | 4.64 | 14.79 |
| Cash Ratio | 11.43 | 11.43 | 32.79 | 53.49 | 68.63 | 59.58 | 11.87 | 5.37 | 11.38 | 4.31 | 14.47 |
| Asset Turnover | — | — | — | 0.02 | 0.07 | 0.12 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | 160.56 | 177.66 | 34.12 | — | — | — | — | — |
XBIT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
XBiotech Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | 22.4% | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | 77.4% | — | — | — | — |
| FCF Yield | — | — | — | — | 19.7% | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 87.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 22.4% | 87.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $30M | $30M | $30M | $30M | $31M | $46M | $36M | $35M | $32M | $31M |
Peer Comparison
Compare XBIT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 XBITYou | $76M | -2.0 | — | — | — | — | -19.2% | -164.8% | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 ARQT | $3B | -158.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 DAWN | $2B | -20.7 | — | — | 89.1% | -80.8% | -22.7% | -30.5% | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 NUVL | $8B | -17.5 | — | — | — | — | -36.7% | -32.5% | — |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 SANA | $918M | -3.0 | — | — | — | — | -99.2% | -86.1% | — |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
See XBIT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XBIT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare XBIT vs RCUS
Side-by-side business, growth, and profitability comparison vs Arcus Biosciences, Inc..
Start ComparisonXBIT — Frequently Asked Questions
Quick answers to the most common questions about buying XBIT stock.
What is XBiotech Inc.'s P/E ratio?
XBiotech Inc.'s current P/E ratio is -2.0x. The historical average is 1.3x.
What is XBiotech Inc.'s ROE?
XBiotech Inc.'s return on equity (ROE) is -19.2%. The historical average is -36.3%.
Is XBIT stock overvalued?
Based on historical data, XBiotech Inc. is trading at a P/E of -2.0x. Compare with industry peers and growth rates for a complete picture.